




RealRate

MEDICINAL PRODUCTS 2023

Biomerica INC
Rank 26 of 55





MEDICINAL PRODUCTS 2023

Biomerica INC
Rank 26 of 55



The relative strengths and weaknesses of Biomerica INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomerica INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Biomerica INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 164%, being 12% points above the market average of 152%.

Input Variable	Value in 1000 USD
Assets, Current	9,427
Assets, Non-Current	1,398
General and Administrative Expense	21,593
Goodwill	170
Liabilities, Current	2,011
Liabilities, Non-Current	1,038
Other Assets	165
Other Compr. Net Income	-26
Other Expenses	24
Other Liabilities	0
Other Net Income	27
Other Revenues	18,871
Property, Plant and Equipment, Net	214
Research and Development	1,812

Output Variable	Value in 1000 USD
Liabilities	3,049
Assets	11,374
Expenses	23,429
Revenues	18,871
Stockholders Equity	8,325
Net Income	-4,531
Comprehensive Net Income	-4,544
BaseVar	28,388
ECR before LimitedLiability	95%
Economic Capital Ratio	164%